Cargando…

Dexamethasone‐Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High‐Dose Cisplatin: A Randomized Noninferiority Study

BACKGROUND: To reduce the overall exposure to dexamethasone (DEX) in patients receiving cisplatin‐based chemotherapy, we evaluated the noninferiority of DEX on day 1, with or without low‐dose DEX on days 2 and 3, combined with an oral fixed‐dose combination of netupitant and palonosetron (NEPA), com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Celio, Luigi, Cortinovis, Diego, Cogoni, Alessio Aligi, Cavanna, Luigi, Martelli, Olga, Carnio, Simona, Collovà, Elena, Bertolini, Federica, Petrelli, Fausto, Cassano, Alessandra, Chiari, Rita, Zanelli, Francesca, Pisconti, Salvatore, Vittimberga, Isabella, Letizia, Antonietta, Misino, Andrea, Gernone, Angela, Bonizzoni, Erminio, Pilotto, Sara, De Placido, Sabino, Bria, Emilio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Symptom Management and Supportive Care
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488764/ https://www.ncbi.nlm.nih.gov/pubmed/34101934 http://dx.doi.org/10.1002/onco.13851

Ejemplares similares

Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study
por: Celio, Luigi, et al.
Publicado: (2022)

Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study)
por: Celio, Luigi, et al.
Publicado: (2023)

Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study
por: Caputo, Roberta, et al.
Publicado: (2020)

Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
por: Shirley, Matt
Publicado: (2021)

Correction to: Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
por: Shirley, Matt
Publicado: (2021)

Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice
por: Aapro, Matti, et al.
Publicado: (2022)

Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron
por: Lorusso, Vito
Publicado: (2016)

Every‐other‐day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the “Rete Ematologica Pugliese”
por: Di Renzo, Nicola, et al.
Publicado: (2019)

Netupitant and palonosetron trigger NK(1) receptor internalization in NG108-15 cells
por: Thomas, Ajit G., et al.
Publicado: (2014)

Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant–palonosetron combination
por: Janicki, Piotr K
Publicado: (2016)

Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin’s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation
por: Di Renzo, Nicola, et al.
Publicado: (2021)

The First Oral Fixed-Dose Combination of Netupitant and Palonosetron for the Treatment of Chemotherapy-Induced Nausea and Vomiting
por: Coyne, Joseph W.
Publicado: (2016)

Drug–drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data
por: Natale, James J, et al.
Publicado: (2015)

Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA)
por: Lorusso, Vito, et al.
Publicado: (2020)

Profile of Antiemetic Activity of Netupitant Alone or in Combination with Palonosetron and Dexamethasone in Ferrets and Suncus murinus (House Musk Shrew)
por: Rudd, John A., et al.
Publicado: (2016)

Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)
por: Baron-Hay, Sally, et al.
Publicado: (2019)

Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)
por: Navari, Rudolph M
Publicado: (2014)

Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic
por: Hesketh, Paul J., et al.
Publicado: (2017)

Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy‐Induced Nausea and Vomiting
por: Gilmore, James, et al.
Publicado: (2018)

Safety and efficacy of netupitant/palonosetron and dexamethasone in classical Hodgkin’s lymphoma patients with inadequate chemotherapy-induced nausea and vomiting prophylaxis with palonosetron and dexamethasone: a single-center real-life experience
por: Zilioli, Vittorio R, et al.
Publicado: (2020)

Anti-emetic Action of the Brain-Penetrating New Ghrelin Agonist, HM01, Alone and in Combination With the 5-HT(3) Antagonist, Palonosetron and With the NK(1) Antagonist, Netupitant, Against Cisplatin- and Motion-Induced Emesis in Suncus murinus (House Musk Shrew)
por: Rudd, John A., et al.
Publicado: (2018)

Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials
por: Celio, Luigi, et al.
Publicado: (2012)

Corrigendum: Anti-emetic Action of the Brain-Penetrating New Ghrelin Agonist, HM01, Alone and in Combination With the 5-HT(3) Antagonist, Palonosetron and With the NK(1) Antagonist, Netupitant, Against Cisplatin- and Motion-Induced Emesis in Suncus murinus (House Musk Shrew)
por: Rudd, John A., et al.
Publicado: (2018)

NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK
por: Cawston, Helene, et al.
Publicado: (2017)

Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial
por: Spinelli, Tulla, et al.
Publicado: (2014)

Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India
por: Vaswani, Bharat, et al.
Publicado: (2020)

Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective
por: Nilsson, Jonas, et al.
Publicado: (2022)

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
por: Aapro, Matti, et al.
Publicado: (2016)

The involvement of TRPV1 in emesis and anti-emesis
por: Rudd, John A, et al.
Publicado: (2015)

The Effectiveness of an Oral Fixed-Dose Combination of Netupitant and Palonosetron (NEPA) in Patients With Multiple Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Observational Indian Study
por: Vaswani, Bharat, et al.
Publicado: (2022)

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
por: Hesketh, P. J., et al.
Publicado: (2014)

Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience
por: Loteta, Barbara, et al.
Publicado: (2021)

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
por: Gralla, R. J., et al.
Publicado: (2014)

Netupitant PET imaging and ADME studies in humans
por: Spinelli, Tulla, et al.
Publicado: (2014)

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
por: Aapro, M., et al.
Publicado: (2014)

Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis
por: Botteman, Marc, et al.
Publicado: (2019)

Rare causes of emesis
por: Popa, Stefan L., et al.
Publicado: (2020)

Emesis in a Horse
por: Lowe, William Herbert
Publicado: (1884)

Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron
por: Bajetta, Emilio, et al.
Publicado: (2009)

Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy‐Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial
por: van der Vorst, Maurice J.D.L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lt6msombu40jqvvq31ucotflba